The impact of COVID-19 in a cohort of patients with systemic sclerosis

COVID-19 brought with it unknowns related to systemic sclerosis. To know the clinical evolution and prognosis of COVID-19 in a cohort of patients with systemic sclerosis. During the pandemic, we had digital contact with a cohort of 197 patients with SSc. If they had any condition that met the suspec...

Full description

Saved in:
Bibliographic Details
Published inRevista medica del Instituto Mexicano del Seguro Social Vol. 61; no. 2; p. 163
Main Authors Cruz-Domínguez, María Del Pilar, Morales-Montalvo, Susana Isabel, Vera-Lastra, Olga Lidia, López-Zamora, Berenice, Ordoñez-González, Irvin, Medina-García, Gabriela, López-Burgos, Cinthya Paola, Montes-Cortés, Daniel Héctor, Jara-Quezada, Luis Javier
Format Journal Article
LanguageSpanish
Published Mexico 01.03.2023
Subjects
COVID-19 - complications
Humans
Immunosuppressive Agents - therapeutic use
Lung Diseases, Interstitial - diagnosis
SARS-CoV-2
Scleroderma, Systemic - complications
Scleroderma, Systemic - diagnosis
Scleroderma, Systemic - drug therapy
COVID-19
Coronavirus Infections
Prognosis
Scleroderma, Systemic
Online AccessGet more information

Cover

More Information
Summary:COVID-19 brought with it unknowns related to systemic sclerosis. To know the clinical evolution and prognosis of COVID-19 in a cohort of patients with systemic sclerosis. During the pandemic, we had digital contact with a cohort of 197 patients with SSc. If they had any condition that met the suspected definition of COVID-19, they underwent polymerase chain reaction testing for SARS-CoV-2; they were treated on an outpatient or hospital basis without interfering with their treatment. They followed their evolution every 24 hours until they became asymptomatic or died. Thirteen patients (6.6%), nine diffuse cutaneous (dcSSc), and four limited cutaneous (lcSSc) developed COVID-19 during nine months of follow-up. The immunosuppressants used at the time of the disease were: mycophenolate mofetil, methotrexate, and prednisone, in low doses. Seven patients had interstitial lung disease (ILD). The main symptoms were chest pain, cough, dyspnea, dysgeusia, and anosmia, 1 with mild symptoms without pneumonia, 11 with mild pneumonia, and one with severe pneumonia that required hospital management. Only one (7.7%) presented severe pneumonia, was hospitalized, and died. COVID-19 disease in patients with SSc can be overcome in most cases, even when they are ILD and were using immunosuppressants at the time of infection with the SARS-CoV-2 virus.
ISSN:2448-5667